# BPC-157 TB-500 dosage and pharmacokinetics in the research literature > BPC-157 TB-500 dosage has no validated human basis: no blend PK exists, BPC-157's elimination half-life ran under 30 minutes in animal PK, and TB-500 data are for full-length Thymosin Beta-4. A cited research-context digest, not dosing guidance. There is no validated human pharmacokinetic profile for the blend, and no controlled dose-finding study. What exists is single-compound animal PK, a short BPC-157 half-life, and a fragment-versus-full-length gap on the TB-500 side. We describe doses only as studied in a species, never as guidance. ## What the pharmacokinetic record actually contains BPC-157 TB-500 dosage is, in the research literature, an open entry. No validated human pharmacokinetic half-life exists for either constituent at research-use doses, and none for the blend. What the record holds is a single formal pharmacokinetic study of one component and a pair of human safety studies of the wrong molecule on the other side. For BPC-157, the first formal PK/ADME characterization reported linear pharmacokinetics, a very short elimination half-life of under 30 minutes, modest intramuscular bioavailability — roughly 14-19% in rats and 45-51% in dogs — and rapid breakdown into small peptide fragments that enter normal amino-acid metabolism, with excretion via urine and bile [5]. A short half-life is why community schedules invoke frequent administration; it is not, in itself, a validated dose. This page reads as [half-life and reconstitution in the research literature](/pharmacokinetics-and-dosing), not as a protocol. ## Why there is no validated per-day dose for the blend The bpc-157 tb-500 blend dosage per day that circulates in community protocols has no controlled-trial basis. Commercial research-product labeling commonly pairs the two peptides at fixed combined masses per vial — for example ~10 mg BPC-157 plus ~10 mg TB-500 — but no peer-reviewed combination dose-finding study exists to support any per-day figure. The component animal doses do not translate into a human daily amount. BPC-157 rodent studies commonly express dose per body weight, frequently around 10 µg/kg and 10 ng/kg, with gastric-ulcer cytoprotection studied at 400-800 ng/kg in rats [1]. TB-500 / Thymosin Beta-4 animal work spans a wide range — for instance 2-18 mg/kg intraperitoneally in a rat embolic-stroke dose-response study, and 150 µg twice weekly intraperitoneally for six months in a muscular-dystrophy model [4]. These are per-kilogram, per-species, per-route figures from animal experiments, not human daily doses. ## Half-life, the TB-500 identity gap, and the cycling question The half-life picture is asymmetric. BPC-157's elimination half-life was under 30 minutes in the rat/dog PK study [5]. On the TB-500 side, the human pharmacokinetic data are not for the heptapeptide at all — they are for full-length Thymosin Beta-4. Intravenous Thymosin Beta-4 showed dose-proportional PK in healthy volunteers, with half-life increasing at higher doses [6][7], but no specific half-life is established for the Ac-LKKTETQ fragment that is actually sold as TB-500. That fragment-versus-full-length gap is the central caveat of the TB-500 leg: the molecule synthesized and characterized as TB-500 is the N-acetylated 17-23 fragment of Thymosin Beta-4 [8], while the efficacy and human safety data lean on the full-length parent protein. Any dosing inference for TB-500 inherits this mismatch. ## Routes studied in the component literature When people search wolverine injection, they are asking about administration. The honest answer points to the [routes studied in animal models](/pharmacokinetics-and-dosing#routes-studied), not to a human protocol. In the underlying research those routes span subcutaneous and intramuscular (the predominant community routes for the blend, not drawn from controlled human efficacy trials), intraperitoneal (predominant in the rodent efficacy studies for both peptides [1][4]), intravenous (the human Phase 1 work on full-length Thymosin Beta-4 [6][7], and a BPC-157 IV safety pilot), local or intra-lesional and topical (individual-compound wound and tendon models), and oral or peroral, where BPC-157 is studied as a "stable gastric" peptide. None of these is a validated route for the assembled blend in humans. ## Oral vs. parenteral administration in preclinical models The bpc 157 tb 500 oral question turns on a real asymmetry. BPC-157 is described in the literature as a stable gastric peptide, and oral products are marketed; but the only formal PK characterization measured intramuscular bioavailability — about 14-19% in rats, 45-51% in dogs — not validated oral exposure, and it documented rapid breakdown into small fragments [5]. Parenteral routes (subcutaneous, intramuscular, intraperitoneal, intravenous) dominate the underlying efficacy and PK studies for both peptides [1][4][5][6][7]. No validated oral pharmacokinetics exist for the blend, so oral and parenteral cannot be presented as interchangeable. ## Reconstitution and handling — a research-chemical question Reconstitution is the most common practical question about the blend, and it is a handling question about a research chemical, not human-use guidance. Both constituents are supplied as lyophilized powders for research use, reconstituted in bacteriostatic or sterile water and refrigerated. A frequent community practice is to reconstitute the two peptides separately or in a shared vial. The unavoidable caveat: in unregulated material, product identity, purity, and the actual BPC-157:TB-500 ratio are not guaranteed — which compounds the existing TB-500 fragment-versus-full-length identity issue. --- A hand-drawn lab notebook on the BPC-157 TB-500 blend — each component study inked from its source and the missing combination trial circled in the margin in red, with no clinic behind the page and nothing here dispensed or sold.